BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BIO is not a good buy right now for a beginner long-term investor with available capital who wants an immediate, straightforward entry. The stock has weak short-term technicals, soft analyst sentiment, and recent financial results showed meaningful pressure on profitability. While hedge funds are accumulating and the company has some product growth momentum, the current setup does not support an attractive long-term buy at this price. I would not buy it now; I would wait.
BIO is in a bearish technical posture. The MACD histogram is negative at -4.131, indicating downward momentum, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a broader downtrend. RSI_6 at 26.739 suggests the stock is near oversold conditions, but not enough to override the trend. Price at 252.5 is below the pivot of 268.697 and only slightly above S1 at 248.921, so the stock is trading near support rather than breaking higher. The short-term trend remains weak, and the pattern-based expectation points to more downside in the near term.
["Q1 2026 ddPCR instrument revenue grew 24% YoY, driven by the QX700 platform.", "Management is shifting acquisition focus toward established, revenue-producing targets, which could improve capital allocation.", "Hedge funds are reportedly buying aggressively over the last quarter.", "The stock is near technical support levels, which may limit further downside in the short term."]
["Q1 2026 revenue growth was only 1.14% YoY, showing sluggish top-line expansion.", "Net income and EPS were sharply negative, indicating severe profitability weakness in the latest quarter.", "Gross margin declined to 52.25%, showing margin pressure.", "Wells Fargo cut its price target to $290 from $320 and maintained Equal Weight after a Q1 organic growth miss and margin pressure.", "Citi downgraded the stock to Neutral from Buy and cut its target sharply to $300 from $375.", "Recent news says the Middle East conflict hurt demand and margins and forced a reduction in FY26 guidance.", "The technical trend remains bearish with no AI Stock Picker or SwingMax signal."]
In Q1 2026, Bio-Rad posted revenue of about $592.1 million, up 1.14% year over year, which shows only modest growth. However, profitability weakened sharply: net income fell to -$527.1 million and EPS dropped to -$19.55. Gross margin also declined to 52.25% from the prior year. The latest quarter season is Q1 2026, and the overall takeaway is that growth is present in select product areas but earnings quality and margins are under pressure.
Analyst sentiment has turned more cautious. Citi downgraded BIO to Neutral from Buy and cut the target to $300 from $375, citing a weak recovery outlook in process chromatography and uncertainty in China diagnostics. Wells Fargo also lowered its target twice, most recently to $290 from $320, while keeping Equal Weight after a Q1 organic growth miss and margin pressure. UBS remains more constructive with a Buy rating, but even there the tone was cautious due to messy margins and headwinds. Overall, Wall Street is leaning neutral-to-cautious rather than bullish.
